Colorectal Polyps and Colorectal Carcinoma Pathology

Adenoma-Carcinoma Sequence (Classic Model)

Molecular Subtypes and Microsatellite Instability Pathway

• Microsatellite Instability (MSI-H pathway): Defective mismatch repair genes (MLH1, MSH2, MSH6, PMS2) result in inability to correct nucleotide mismatches during DNA replication, leading to accumulation of mutations at repetitive DNA sequences (microsatellites). MSI-H tumors demonstrate a mutator phenotype with thousands of mutations, often associated with better prognosis but distinct immunological and treatment characteristics. This pathway accounts for approximately 15% of sporadic CRC and nearly 100% of Lynch syndrome-related CRC.

• CpG Island Methylator Phenotype (CIMP): Epigenetic silencing of tumor suppressor genes through aberrant DNA methylation of CpG islands in gene promoter regions, particularly affecting MLH1, CDKN2A/p16, and VHL. CIMP-high tumors typically occur in the proximal colon, present at advanced stage, and have worse prognosis.

• Chromosomal Instability (CIN): The most common pathway (85% of sporadic CRC), characterized by loss of heterozygosity (LOH), aneuploidy, and gross chromosomal rearrangements. Results from defects in chromosomal segregation and checkpoint mechanisms rather than mismatch repair genes.

Epithelial-Mesenchymal Transition (EMT) and Invasion

Polyp-Specific Pathophysiology

• Hyperplastic polyps: Result from delayed shedding of epithelial cells rather than increased proliferation, with preservation of normal maturation architecture. Carry minimal malignant potential (<1%).

• Serrated adenomas (sessile serrated lesions): Characterized by prominent basal crypt serration with cytoplasmic mucin and abnormal maturation, frequently associated with MLH1 methylation and MSI-H pathway. Represent important precursor lesions with 10-15% malignant potential if advanced.

• Traditional adenomas (tubular, tubulovillous, villous): Display loss of normal goblet cell differentiation, increased nuclear-to-cytoplasmic ratio, crowding and stratification of nuclei, and disruption of crypt architecture. Villous histology carries highest malignant potential (approximately 40% with high-grade dysplasia).

Genetic Predisposition Syndromes

• Familial Adenomatous Polyposis (FAP): Autosomal dominant inheritance of germline APC mutation resulting in development of hundreds to thousands of adenomas by age 40, with virtually 100% cancer risk if untreated by age 50. Demonstrates complete penetrance and early age of onset.

• Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer - HNPCC): Autosomal dominant inheritance of germline mismatch repair gene mutations (MLH1, MSH2, MSH6, PMS2, EPCAM deletion) conferring 50-80% lifetime CRC risk and often presenting before age 50 with proximal colon predominance. Associated with increased risk of extracolonic malignancies (endometrial, ovarian, gastric, pancreatic).

• Peutz-Jeghers Syndrome: Germline STK11 mutation resulting in hamartomatous polyps with increased CRC risk (approximately 39% lifetime). Characterized by mucosal pigmentation and Brunner gland hyperplasia in hamartomas.

• Juvenile Polyposis Syndrome: Germline SMAD4 or BMPR1A mutations resulting in hamartomatous polyps and 10-15% CRC risk. Characterized by cystic dilatation of glands.

Chronic Inflammatory Conditions

• Ulcerative Colitis: Chronic mucosal inflammation with increased risk proportional to disease duration (1-2% at 10 years, 8-10% at 20 years) and extent (pancolitis > left-sided colitis). Dysplasia-associated lesion or mass (DALM) represents increased cancer risk.

• Crohn's Disease: Increased CRC risk approximately 4-20 fold compared to general population, particularly with long-standing colonic involvement.

Modifiable Risk Factors

• Dietary factors: High red and processed meat consumption, low dietary fiber, low vegetable intake, high fat diet
• Alcohol consumption: Particularly beer and spirits (dose-dependent risk)
• Tobacco use: Increases adenoma incidence and progression
• Obesity: Particularly in men; proposed mechanisms include insulin resistance and chronic inflammation
• Physical inactivity: Independent risk factor for adenoma and cancer development
• Advanced age: Exponential increase in incidence after age 50

Non-Modifiable Risk Factors

• Family history: Relative risk of 2-3 fold with first-degree relatives affected
• Prior adenoma: History of adenoma increases risk of metachronous lesions
• Primary sclerosing cholangitis (PSC): Associated with ulcerative colitis and markedly increased CRC risk

Early-Stage Disease (Adenomas and Early Carcinoma)

• Asymptomatic detection: Majority of adenomas and early-stage carcinomas detected on screening in asymptomatic individuals, emphasizing importance of surveillance programs
• Occult blood loss: Fecal occult blood test (FOBT) positivity indicates need for colonoscopic evaluation; represents microscopic bleeding from polypoid lesions or friable mucosa
• Minor lower GI symptoms: Occasional loose stools, minor change in bowel habits, or mild cramping associated with polypoid lesions, particularly if obstructing

Advanced Local Disease

• Change in bowel habits: Persistent diarrhea or constipation (altered from baseline), often with pencil-thin or ribbon-like stools suggesting stricturing from annular lesions
• Lower abdominal pain and cramping: Related to luminal narrowing, obstruction, or invasion through muscularis propria and into visceral peritoneum
• Gross hematochezia: Bright red blood per rectum, often mixed with stool, indicates left-sided lesions with vascular invasion; melena suggests more proximal lesions
• Anemia symptoms: Fatigue, dyspnea, tachycardia secondary to iron deficiency anemia from chronic blood loss; right-sided lesions particularly prone to occult bleeding

Advanced Systemic Disease

• Constitutional symptoms: Unintentional weight loss (>10 pounds), fatigue, and malaise accompanying advanced disease with systemic inflammatory response
• Abdominal distention and vomiting: Mechanical bowel obstruction from circumferential annular lesions ("napkin-ring" appearance), typically left-sided
• Acute abdomen findings: Acute peritonitis from perforation of obstructed segment with fecal soilage and bacterial translocation; associated with severe pain and sepsis

Physical Examination Findings

• Abdominal mass: Palpable mass in left lower quadrant (sigmoid/rectosigmoid), right lower quadrant (cecum/ascending colon), or epigastrium (hepatic flexure)
• Hepatomegaly: Indicates hepatic metastases from advanced disease with portal vein invasion
• Ascites: Suggests peritoneal involvement or advanced hepatic metastases with portal hypertension
• Lymphadenopathy: Supraclavicular or axillary lymphadenopathy indicates distant metastatic disease
• Rectal examination findings: Palpable mass on digital rectal exam (approximately 10% of rectal cancers within reach), blood on gloved finger

Laboratory and Imaging Correlates

• Carcinoembryonic antigen (CEA) elevation: Elevated preoperatively in 40-50% of stage II-III disease and >80% of stage IV disease; limited sensitivity and specificity making it inappropriate for screening but useful for prognostication and monitoring
• Anemia parameters: Microcytic hypochromic anemia from chronic iron deficiency (low ferritin, low serum iron, elevated TIBC)
• Elevated alkaline phosphatase and elevated transaminases: Indicates hepatic involvement
• CT imaging correlates: Wall thickening >5mm, shouldering of margins, shouldering of the wall, and loss of normal fat planes suggesting invasion

Colonoscopic Features and Gross Pathology

• Adenomatous polyps: Variable gross appearance depending on histological type. Tubular adenomas typically small (<1 cm), sessile, tan-pink with smooth surface. Tubulovillous adenomas intermediate size and appearance. Villous adenomas typically large (>2 cm), sessile with characteristic velvety or carpet-like appearance with surface irregularity. Paris classification describes morphology: type I (protruding), type II (superficial), type III (excavated/depressed).

• Serrated adenomas and sessile serrated lesions: Often subtle endoscopic appearance with ill-defined margins, frequently missed on colonoscopy. Characterized by loss of normal pit pattern on narrow-band imaging and indistinct surface.

• Invasive carcinoma: Ulcerated, hemorrhagic, friable mucosa with rolled or overhanging edges. May demonstrate napkin-ring configuration with circumferential narrowing, apple-core or stricturing appearance. Friability with contact bleeding distinguishes from benign polyps.

Histological Findings

Adenomatous Polyps - Dysplasia Grading

• Low-grade dysplasia (LGD): Nuclei enlarged with increased nuclear-to-cytoplasmic ratio, crowding and stratification of nuclei confined to basal half of crypts. Preserved maturation with goblet cells and mucin toward crypt lumen. Mitotic figures present but without abnormal forms. Architecture demonstrates elongation and branching of crypts without significant complexity.

• High-grade dysplasia (HGD): Nuclear enlargement and stratification extending to surface epithelium with loss of maturation gradient. Irregular nuclear membranes, coarse chromatin, prominent nucleoli. Increased mitotic rate with abnormal mitotic figures. Loss of goblet cells and mucin. Irregular crypt architecture with cribriform patterns. Mucin depletion is hallmark finding.

• Villoglandular (tubulovillous) adenoma: Demonstrates mixture of tubular and villous components. Villi represent finger-like projections of lamina propria lined by dysplastic epithelium, in contrast to normal colonic mucosa with crypts but no villi. Increased surface area predicts higher malignant potential.

Serrated Lesions

• Hyperplastic polyps: Prominent basal cryptal serration but maintained maturation with normal goblet cell differentiation apically. Small size, low-grade lesions with minimal dysplasia. Normal CpG island methylator pattern (CIMP) status.

• Sessile serrated lesion/polyp (SSL/SSP): Exaggerated basal crypt serration extending into muscularis mucosae with cytoplasmic eosinophilia and reduced mucin in basal crypts (contrast to hyperplastic). Horizontal crypt orientation in deeper portions. Often demonstrates MLH1 methylation and associated MSI-H phenotype. May demonstrate dysplasia (then classified as serrated adenoma with dysplasia).

• Traditional serrated adenoma (TSA): Serration throughout crypt depth with prominent cytoplasmic eosinophilia and mucin depletion, combined with dysplastic features (nuclear crowding, stratification). Intermediate morphology between SSL and conventional adenoma.

Invasive Carcinoma - Adenocarcinoma Subtypes

• Tubular adenocarcinoma (most common, ~60%): Infiltrating tubules lined by columnar epithelium with nuclear enlargement, increased mitotic activity, and desmoplastic stromal response. Glandular differentiation preserved.

• Mucinous adenocarcinoma (10-15%): Malignant epithelium suspended in pools of extracellular mucin (signet-ring cells emerging from mucin lakes). Worse prognosis than tubular, higher propensity for peritoneal involvement. Associated with MSI-H pathway and CIMP.

• Signet-ring cell carcinoma (1-3%): Individual tumor cells with eccentric nuclei pushed peripherally by abundant intracytoplasmic mucin (resembling signet rings). Diffuse infiltrative pattern without gland formation. Poor prognosis with propensity for linitis plastica-type growth.

• Neuroendocrine differentiation: Small percentage of carcinomas demonstrate neuroendocrine features (chromogranin/synaptophysin positivity); associated with aggressive behavior.

• Well-differentiated: Predominantly tubular glands, minimal nuclear atypia, <50% solid areas
• Moderately differentiated: Mixture of glandular and solid areas, moderate nuclear atypia
• Poorly differentiated: Predominantly solid/cribriform areas, marked nuclear atypia, high mitotic rate, <50% gland formation

TNM Staging and Invasion Assessment

• Depth of invasion (T-staging):
• T1 (intramucosal/early carcinoma): Carcinoma confined to mucosa and submucosa, not invading muscularis propria. Defines "early carcinoma" in polypoid lesions; carries approximately 5% lymph node metastasis risk with endoscopic polypectomy
• T2: Invades into but not through muscularis propria (visible as smooth muscle layer on H&E)
• T3: Invades through muscularis propria into subserosal fat (pericolorectal adipose tissue); represents most common stage at presentation
• T4a: Invades through visceral peritoneum
• T4b: Directly inv

Immediate stabilisation (complicated presentations)

• Obstructing or perforated tumor: NPO, isotonic crystalloid resuscitation, nasogastric decompression, broad-spectrum antibiotics if perforated. Perforation with peritonitis requires emergent laparotomy; a self-expanding metal stent may be used as a bridge to surgery in left-sided malignant obstruction per NCCN, allowing bowel prep and one-stage resection instead of a diverting colostomy.

Polyps — endoscopic therapy first

• Cold snare polypectomy: preferred for diminutive/small polyps; endoscopic mucosal resection for large sessile or laterally spreading lesions. Complete removal interrupts the adenoma-carcinoma sequence.
• Surveillance colonoscopy: interval set by number, size, and histology of resected lesions (US Multi-Society Task Force on Colorectal Cancer). Average-risk screening begins at age 45 (USPSTF).
• Contraindicated as sole therapy: endoscopic removal of a malignant polyp with adverse features — positive/indeterminate margin, lymphovascular invasion, poor differentiation, or deep submucosal invasion — mandates segmental colectomy with regional lymphadenectomy.

Invasive carcinoma — definitive management

• Oncologic resection: en bloc segmental colectomy with high vascular ligation and adequate regional lymph node harvest for accurate staging (NCCN).
• Rectal cancer: total mesorectal excision, usually after neoadjuvant chemoradiation or total neoadjuvant therapy for locally advanced disease (NCCN).
• Adjuvant chemotherapy: fluoropyrimidine plus oxaliplatin (FOLFOX) for node-positive (stage III) disease; considered for high-risk stage II.

Metastatic and escalation options

• Anti-VEGF monoclonal antibody (bevacizumab) added to cytotoxic backbone.
• Anti-EGFR monoclonal antibody (cetuximab): only for RAS wild-type, left-sided tumors — contraindicated with KRAS/NRAS mutation, since downstream constitutive signaling makes receptor blockade futile.
• Immune checkpoint inhibitor (pembrolizumab) for MSI-H/dMMR disease, reflecting high neoantigen burden.

Hereditary syndromes

• FAP: prophylactic total proctocolectomy with ileal pouch-anal anastomosis or total colectomy with ileorectal anastomosis, typically in the late teens.
• Lynch syndrome: colonoscopy every 1-2 years beginning in the early twenties, plus gynecologic surveillance/risk-reducing hysterectomy-BSO after childbearing.

Disease-related — emergencies flagged

• Large bowel obstruction (EMERGENCY): circumferential napkin-ring/apple-core annular left-sided lesion; signalled by distention, obstipation, vomiting, and dilated colon with air-fluid levels on imaging. Closed-loop obstruction with a competent ileocecal valve risks cecal blowout.
• Perforation with peritonitis (EMERGENCY): pressure necrosis proximal to an obstructing lesion or direct tumor invasion; free air under the diaphragm, rebound tenderness, sepsis.
• Massive lower GI hemorrhage: erosion into submucosal vessels; hemodynamic instability with hematochezia.
• Iron deficiency anemia: chronic occult loss, typically from right-sided lesions where stool is liquid and bleeding is unnoticed; microcytic anemia with low ferritin.
• Hepatic metastases: portal venous drainage of the colon seeds the liver first; hepatomegaly with elevated alkaline phosphatase. Distal rectal tumors drain via systemic veins and may seed lung first.
• Peritoneal carcinomatosis and malignant ascites: transmural (T4a) spread, especially mucinous subtypes.
• Secretory hypokalemia and dehydration: large distal villous adenoma secreting potassium-rich mucus (McKittrick-Wheelock syndrome).
• Streptococcus gallolyticus (bovis) bacteremia/endocarditis: mucosal disruption permits translocation — a positive blood culture obligates colonoscopy.

Treatment-related

• Post-polypectomy bleeding and perforation: thermal injury to the muscularis; delayed bleeding may occur days later. Perforation is an emergency.
• Post-polypectomy electrocoagulation syndrome: transmural burn without perforation — pain and fever with no free air; managed medically.
• Anastomotic leak (EMERGENCY): ischemia or tension at the staple line; fever, tachycardia, and peritonitis on postoperative days 3-7.
• Oxaliplatin: cumulative sensory peripheral neuropathy with cold-induced dysesthesia.
• 5-fluorouracil: myelosuppression and mucositis, severe in DPD deficiency; irinotecan: acute cholinergic and delayed diarrhea (UGT1A1 polymorphism).
• Bevacizumab: impaired wound healing, hypertension, thrombosis, and GI perforation.
• Cetuximab: acneiform rash.
• FAP after colectomy: duodenal/ampullary adenocarcinoma and desmoid tumors become the leading causes of death.

• Mutation order is the answer: APC → KRAS → TP53 ("At the Knee of 53"). APC loss initiates the adenoma; KRAS drives adenoma growth; TP53 loss permits invasion. A stem describing the earliest change wants APC/Wnt-β-catenin.
• Villous = villainous: villous histology, size >1 cm, and high-grade dysplasia are the three features predicting malignant transformation. A large distal villous adenoma causing watery diarrhea with hypokalemia is the classic secretory-adenoma vignette.
• Side matters: right-sided (proximal) cancers bleed occultly and present with iron deficiency anemia; left-sided cancers obstruct and give apple-core/napkin-ring lesions with pencil-thin stools. New iron deficiency anemia in a man or postmenopausal woman = colonoscopy, not empiric iron.
• The single most-tested next step: Streptococcus gallolyticus (formerly S. bovis) bacteremia or endocarditis → colonoscopy.
• FAP vs Lynch: FAP = germline APC on chromosome 5q, hundreds-to-thousands of polyps, 100% cancer risk → prophylactic colectomy. Gardner adds osteomas, desmoids, supernumerary teeth, and congenital hypertrophy of the retinal pigment epithelium; Turcot adds CNS tumors. Lynch = germline mismatch repair mutation, few polyps, proximal/right-sided, MSI-H, and endometrial carcinoma is the second most common malignancy.
• MSI-H is prognostically favorable in early stage and predicts response to checkpoint inhibitors in metastatic disease — but MSI-H stage II tumors generally do not benefit from single-agent fluoropyrimidine adjuvant therapy.
• CEA is never a screening test: use it for prognosis and postoperative surveillance for recurrence only. A normal CEA does not exclude cancer.
• Common distractors: hyperplastic polyps are the most common polyp and are essentially benign — but a large, right-sided sessile serrated lesion is premalignant via MLH1 promoter hypermethylation, not the classic APC pathway. Also, hamartomas in Peutz-Jeghers are themselves low-risk; the cancer risk is systemic (breast, pancreas, gynecologic), not just colonic.